Hyoscyamine, Methenamine, Methylene Blue, Phenyl Salicylate, And Sodium Phosphate

Introduction Overview

Generic Name

hyoscyamine, methenamine, methylene blue, phenyl salicylate, and sodium phosphate

Brand Name

Uretron D/S

Dosage Form

Oral tablet

Drug Class

Urinary antispasmodics

Pharmacokinetics

Absorption: Uretron D/S is administered orally as a combination tablet, each constituent demonstrating distinct absorption profiles. Hyoscyamine, a belladonna alkaloid, is well absorbed from the gastrointestinal tract, with peak plasma concentrations typically attained within 30 to 60 minutes post-ingestion, allowing rapid onset of antispasmodic activity. Methenamine is acid-labile and decomposes in acidic environments such as the stomach, releasing formaldehyde, which exerts local antiseptic effects. Methylene blue, a cationic dye, is also efficiently absorbed orally and attains peak plasma levels within hours. Phenyl salicylate is hydrolyzed to salicylate and phenol; salicylates are readily absorbed from the gastrointestinal tract. Sodium phosphate acts mainly as a urinary acidifier and is absorbed systemically to a minimal extent.

Distribution: Hyoscyamine exhibits wide tissue distribution due to its lipophilic nature, readily crossing cellular membranes and binding to muscarinic receptors in the urinary tract smooth muscles to exert spasmolytic effects. It has a volume of distribution approximating 2 to 4 L/kg. Methenamine largely acts locally within the urinary tract after renal excretion, with minimal systemic distribution of its reactive metabolites. Methylene blue distributes extensively into body tissues, including the bladder wall, providing localized antiseptic action. Phenyl salicylate-derived salicylates distribute extensively, penetrating inflamed tissues effectively. Sodium phosphate distribution is limited, primarily influencing systemic acid-base balance and urinary pH.

Metabolism: Hyoscyamine undergoes hepatic metabolism predominantly via hydrolysis and conjugation pathways, forming inactive metabolites excreted renally. Methenamine is non-enzymatically decomposed in acidic urine to formaldehyde and ammonia without significant hepatic metabolism. Methylene blue undergoes hepatic reduction to leukomethylene blue, which is further metabolized and excreted. Phenyl salicylate hydrolyzes to salicylic acid and phenol, with salicylic acid metabolized in the liver mainly via conjugation with glycine and glucuronic acid. Sodium phosphate does not undergo metabolism as its principal action is chemical modification of urinary pH.

Elimination: Hyoscyamine and its metabolites are excreted primarily by the kidneys, with an elimination half-life of approximately 2 to 4 hours. Methenamine and its decomposed formaldehyde exert their effects within the urinary tract; formaldehyde is rapidly cleared via urine, minimizing systemic exposure. Methylene blue and its metabolites are excreted in urine, imparting a characteristic blue-green discoloration of urine, typically lasting several hours post-dose. Phenyl salicylate-derived salicylates are eliminated renally with an elimination half-life ranging from 2 to 4 hours, depending on the individual’s renal function. Sodium phosphate enhances urinary acidification and is eliminated unchanged in the urine. Renal function critically influences the elimination kinetics of all components, necessitating caution in patients with impaired renal clearance.

Dosage Forms

Available Dosage Forms: Uretron D/S is formulated as oral tablets, combining five active components: hyoscyamine, methenamine, methylene blue, phenyl salicylate, and sodium phosphate. These tablets are designed for oral administration to relieve urinary tract discomfort and infections.

Dosages for Adults and Adolescents: The standard dosing regimen for adults involves administering one tablet orally four times daily, typically with meals and at bedtime to optimize symptomatic relief. For children aged 7 years and older, dosing must be individualized and strictly determined by a healthcare provider, considering weight and severity of symptoms. The use in children 6 years and younger is not recommended owing to insufficient safety data and potential adverse effects.

Specific Patient Populations: Use in pediatric populations below seven years is contraindicated. In geriatric patients, there is a paucity of data regarding altered pharmacodynamics or pharmacokinetics; therefore, dose adjustments should be considered cautiously, monitoring for anticholinergic or systemic effects. Patients with renal impairment require careful evaluation due to altered metabolism and excretion of several components, in particular, hyoscyamine and methenamine derivatives, to avoid toxicity. Also, caution is advised in patients with urinary retention or obstruction due to the antispasmodic effects. No alternate formulations such as capsules, liquids, or injectables are commercially available for Uretron D/S; the oral tablet form remains the standard.

Mechanism Of Action

Uretron D/S is a multifaceted combination drug designed to address symptoms and underlying causes of urinary tract discomfort, involving a synergy of pharmacological actions from its five constituent compounds. Hyoscyamine acts as a competitive antagonist of muscarinic acetylcholine receptors, specifically targeting M1 to M5 receptor subtypes located in the smooth muscle of the urinary tract. This inhibition reduces parasympathetic stimulation, leading to relaxation of the detrusor muscle and ureteral smooth muscle, thereby alleviating spasms, cramps, and urinary urgency associated with infection or diagnostic procedures.

Methenamine serves as a urinary antiseptic prodrug. Under acidic urinary conditions facilitated by sodium phosphate, methenamine hydrolyzes to release formaldehyde, a potent bactericidal agent. Formaldehyde exerts nonspecific cross-linking of bacterial proteins and DNA, effectively preventing bacterial proliferation, particularly against common urinary tract pathogens, thus aiding infection eradication.

Methylene blue complements the antiseptic activity of methenamine by exerting antimicrobial effects via redox cycling. It intercalates into bacterial cell membranes, generating reactive oxygen species and disrupting enzymatic functions that are crucial for bacterial survival. Additionally, methylene blue imparts a characteristic blue coloration to urine, which serves as a clinical indicator of drug excretion.

Phenyl salicylate contributes analgesic and anti-inflammatory actions. After hydrolysis, it liberates salicylate, which inhibits cyclooxygenase enzymes COX-1 and COX-2, reducing prostaglandin synthesis responsible for pain and inflammation in the urinary tract mucosa. Sodium phosphate functions primarily as a urinary acidifier, decreasing urine pH to optimize the hydrolysis of methenamine to formaldehyde, thereby enhancing its antibacterial efficacy. Collectively, these mechanisms produce symptomatic relief from urinary tract infections by mitigating muscle spasm, pain, and bacterial load.

Pharmacological Actions

Muscarinic receptor antagonism by hyoscyamine leading to urinary tract smooth muscle relaxation
Urinary antiseptic effect via formaldehyde release from methenamine under acidic urine conditions
Antimicrobial activity through reactive oxygen species generation by methylene blue
Analgesic and anti-inflammatory effects by inhibition of prostaglandin synthesis from phenyl salicylate metabolism
Urine acidification by sodium phosphate to potentiate antimicrobial activity
Reduction of urinary tract spasms and cramps
Alleviation of urinary urgency and frequency symptoms
Complementary synergistic actions of antiseptic and antispasmodic components
Local urinary tract action with minimal systemic absorption for most components
Coloration of urine blue due to methylene blue excretion
Inhibition of bacterial growth to limit infection spread
Relief of inflammation-related bladder discomfort

Therapeutic Or Clinical Uses

Symptomatic relief of urinary tract discomfort including pain, burning, and swelling
Management of urinary tract spasms and cramps associated with infections or diagnostic procedures
Adjunctive treatment of lower urinary tract infections to alleviate symptoms
Reduction of urinary frequency and urgency caused by bladder irritation
Supportive therapy to enhance urinary antiseptic effects via urinary acidification
Relief from bladder muscle spasms resulting from catheterization or instrumentation
Palliative therapy during diagnostic procedures involving the urinary tract
Use in conditions with urinary tract irritation where conventional antibiotics are adjunct
Intervention to minimize discomfort caused by urinary inflammation
Symptom control in recurrent or chronic lower urinary tract infections with mild symptoms
Treatment for urinary tract pain of nonbacterial origin when spasm is evident

Side Or Adverse Effects

Blurred vision potentially associated with anticholinergic effects of hyoscyamine
Dizziness related to systemic anticholinergic activity
Rapid pulse (tachycardia) from muscarinic receptor blockade
Blue-green discoloration of urine attributable to methylene blue excretion
Dry mouth due to reduced salivary secretions
Constipation resulting from gastrointestinal smooth muscle relaxation
Possible allergic reactions including skin rash or urticaria
Headache and mild gastrointestinal upset in some patients
Potential urinary retention especially in patients with prostatic hypertrophy
Rare central nervous system effects such as confusion or hallucinations in sensitive individuals
Photosensitivity related to phenyl salicylate component
Mild nausea or stomach discomfort at initiation of therapy
Possible exacerbation of glaucoma due to anticholinergic action
Increased risk of adverse effects in elderly or in renal impairment

Precautions

Use caution in patients with glaucoma due to risk of increased intraocular pressure
Caution in individuals with urinary retention or obstructive uropathy
Avoid use in patients with known allergy or intolerance to belladonna alkaloids or salicylates
Monitor closely in patients with cardiac conditions such as arrhythmias or tachycardia
Use is not recommended for children 6 years or younger due to safety concerns
Careful assessment in elderly patients owing to increased anticholinergic sensitivity
Adequate hydration advised to enhance urinary clearance and drug efficacy
Regular medical follow-up recommended to assess treatment response and adverse effects
Avoid concomitant use of other drugs with anticholinergic properties unless supervised
Discontinue drug and seek medical consultation if experiencing blurred vision, dizziness, or rapid heartbeat
Inform healthcare provider of all medications to detect potential interactions
Use during breastfeeding should weigh benefits against potential risks
Avoid alcohol or sedatives that may enhance drowsiness or dizziness
Patients should be cautioned about the benign blue discoloration of urine to prevent alarm

Warnings

Not a cure for serious urinary tract infections; requires concomitant antimicrobial therapy as appropriate
May worsen symptoms in patients with pre-existing bladder outlet obstruction
Potential to exacerbate symptoms in patients with severe heart disease or arrhythmias
Risk of anticholinergic toxicity if taken in overdose or with other anticholinergic agents
Avoid abrupt discontinuation without medical advice due to potential symptom rebound
Blue urine coloration is benign but may interfere with certain urine diagnostic tests
Not recommended for use in children younger than 6 years due to lack of safety data
May cause confusion or agitation in elderly or debilitated patients
Can cause additive anticholinergic side effects when combined with other drugs with similar profiles
Use with caution in patients with hepatic or renal impairment due to altered drug clearance
May lead to false-positive results in urine tests involving colorimetric reactions
Avoid use in patients with myasthenia gravis or severe muscle weakness
Patients should report any signs of severe allergic reactions immediately
Use under strict medical supervision during pregnancy and lactation

Contraindication

Known hypersensitivity to hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium phosphate, or any component of the formulation
Children 6 years of age and younger due to safety concerns
Patients with urinary retention or obstructive uropathy
Glaucoma, especially angle-closure glaucoma
Severe ulcerative colitis or ulcerative gastrointestinal diseases
Severe hepatic or renal impairment without specialist supervision
Myasthenia gravis due to potential worsening of muscle weakness
Hypersensitivity or allergy to belladonna alkaloids or salicylates
Patients with significant cardiac arrhythmias or tachycardia
Co-administration with contraindicated drugs causing serious interactions
Severe infections requiring systemic antibiotics rather than symptomatic treatment alone
Pregnancy unless clearly needed and under specialist care
Known G6PD deficiency related to methylene blue component risk
Patients with bladder outlet obstruction leading to risk of urinary retention

Drug Interactions

Contraindicated with acetazolamide, amitriptyline, carbamazepine, codeine, fluoxetine, paroxetine, and many other CNS-active agents due to risk of enhanced anticholinergic or serotonergic effects
Potentially severe interaction with monoamine oxidase inhibitors increasing risk of hypertensive crisis or serotonin syndrome
Use with drugs like pseudoephedrine or other sympathomimetics may enhance tachycardia and hypertension
Concurrent use with other anticholinergic drugs may potentiate adverse effects such as dry mouth, urinary retention, and blurred vision
Interaction with potassium citrate and other alkalinizers may reduce methenamine efficacy by increasing urinary pH
Drugs affecting renal function or urinary pH can alter methenamine and formaldehyde activity
Concomitant use of sulfonamides may increase risk of crystalluria with methenamine
Caution when used with antidepressants, antipsychotics, and narcotics due to additive CNS depression
May interfere with diagnostic urine tests due to methylene blue’s coloration
Enhanced gastrointestinal toxicity when combined with other salicylates or NSAIDs
Numerous potential interactions with antibiotics like ciprofloxacin or levofloxacin necessitating monitoring
Interaction with drugs metabolized by hepatic enzymes due to possible displacement or metabolic inhibition
Potential decreased efficacy with simultaneous use of diuretics or antihypertensives
Must inform healthcare provider of all concurrent medications due to broad spectrum of possible interactions
Avoid alcohol consumption which may exacerbate dizziness, sedation, and hypotension

Preparations Of The Drug

Combined oral tablet formulation containing hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium biphosphate
Administered orally as a single tablet for symptomatic management of urinary tract disorders
Available only by prescription due to complex formulation and need for monitoring
Packaged for oral use with storage instructions to protect from moisture and light to maintain stability
Typically supplied in bottles or blister packs containing measured tablets for precise dosing
No alternative dosage forms (injectable, liquid) currently marketed for this combination
Formulated to provide synergistic antiseptic, antispasmodic, analgesic, and urinary acidifying effects
Contains components requiring caution for allergic patients and those with specific organ dysfunction
Labeling includes detailed instructions to take full course and maintain hydration for efficacy
Manufactured under strict pharmaceutical standards to ensure potency and safety
Color and physical characteristics consistent for identification and patient compliance
Pharmacological components sourced to balance efficacy with tolerability
Requires prescription due to potential side effects, interactions, and contraindications
Distributed under multiple brand names including Phosphasal, Urelle, Uribel, and Uretron D/S